1. Home
  2. BLDE vs NLSP Comparison

BLDE vs NLSP Comparison

Compare BLDE & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLDE
  • NLSP
  • Stock Information
  • Founded
  • BLDE 2014
  • NLSP 2015
  • Country
  • BLDE United States
  • NLSP Switzerland
  • Employees
  • BLDE N/A
  • NLSP N/A
  • Industry
  • BLDE Aerospace
  • NLSP Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLDE Consumer Discretionary
  • NLSP Health Care
  • Exchange
  • BLDE Nasdaq
  • NLSP Nasdaq
  • Market Cap
  • BLDE 285.2M
  • NLSP 12.4M
  • IPO Year
  • BLDE N/A
  • NLSP 2021
  • Fundamental
  • Price
  • BLDE $4.18
  • NLSP $2.50
  • Analyst Decision
  • BLDE Strong Buy
  • NLSP
  • Analyst Count
  • BLDE 2
  • NLSP 0
  • Target Price
  • BLDE $6.25
  • NLSP N/A
  • AVG Volume (30 Days)
  • BLDE 855.2K
  • NLSP 411.8K
  • Earning Date
  • BLDE 08-06-2025
  • NLSP 07-15-2025
  • Dividend Yield
  • BLDE N/A
  • NLSP N/A
  • EPS Growth
  • BLDE N/A
  • NLSP N/A
  • EPS
  • BLDE N/A
  • NLSP N/A
  • Revenue
  • BLDE $251,485,000.00
  • NLSP N/A
  • Revenue This Year
  • BLDE $5.58
  • NLSP N/A
  • Revenue Next Year
  • BLDE $8.56
  • NLSP N/A
  • P/E Ratio
  • BLDE N/A
  • NLSP N/A
  • Revenue Growth
  • BLDE 8.67
  • NLSP N/A
  • 52 Week Low
  • BLDE $2.35
  • NLSP $1.30
  • 52 Week High
  • BLDE $5.17
  • NLSP $15.59
  • Technical
  • Relative Strength Index (RSI)
  • BLDE 62.55
  • NLSP 52.64
  • Support Level
  • BLDE $3.94
  • NLSP $2.16
  • Resistance Level
  • BLDE $4.22
  • NLSP $3.08
  • Average True Range (ATR)
  • BLDE 0.20
  • NLSP 0.24
  • MACD
  • BLDE 0.00
  • NLSP -0.00
  • Stochastic Oscillator
  • BLDE 91.04
  • NLSP 30.21

About BLDE Blade Air Mobility Inc.

Blade Air Mobility Inc is a technology-powered air mobility platform that provides air transportation and logistics for hospitals and is a transporter of human organs for transplant, and for passengers, with helicopter and fixed-wing services predominantly in the Northeast United States, Southern Europe and Western Canada. The company's operating segments are; Passenger, and Medical. Majority of the revenue for the company is generated from its Medical segment which predominantly consists of transportation of human organs for transplant and the medical teams supporting these services. It also offers additional services including donor logistics coordination and support in evaluating potential donor organs. A substantial portion of the company's revenue is generated from the United States.

About NLSP NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

Share on Social Networks: